ArticleAmerican journal of translational research2026
Efficacy and immune-inflammatory modulation of combined glucocorticoid and anti-tuberculosis therapy in patients with bronchial asthma and pulmonary tuberculosis.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the efficacy and immunomodulatory effects of glucocorticoid combination therapy with anti-tuberculosis treatment in patients with asthma complicated by pulmonary tuberculosis.
methodsClinical data of 128 patients with bronchial asthma complicated with pulmonary tuberculosis were retrospectively analyzed. According to the treatment plan, the patients were divided into a control group and an observation group. The improvements in clinical symptoms, lung function indexes, immune and inflammation markers, chest X-ray results, sputum negative conversion rate, and incidence of adverse reactions were compared between the two groups.
resultsPatients in the observation group demonstrated superior improvement in clinical symptoms compared to the control group. After six months of treatment, both groups demonstrated significant improvements in pulmonary function scores relative to baseline, with the observation group showing greater improvement than the control group. Inflammatory and immune markers were significantly reduced in both groups compared to pre-treatment levels, with the reduction being greater in the observation group than in the control group. After 6 months of treatment, lesion absorption and cavitary closure were more favorable in the observation group. At the 6-month follow-up, the bacteriological recurrence rate in the observation group was significantly lower than that of the control group.
conclusionThe combined use of glucocorticoids and anti-tuberculosis drugs provides dual advantages: it effectively controls asthma while enhancing the efficacy of anti-tuberculosis treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.